You have successfully completed the newsletter registration.
We are pleased to welcome you in our mailing list!
Best regards
Your MetrioPharm Blog team
MetrioPharm AG
Bleicherweg 45
CH-8002 Zurich
Newsletter subscription completed
- 25.10.2023 MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
- 30.05.2023 MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
- 08.12.2022 MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
- 12.10.2022 MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)